Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Holding DARE?
Track your performance easily
DARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.67 - $10.72
Previous Close$2.71
Volume89.97K
Average Volume (3M)51.58K
Market Cap
$25.93M
Enterprise Value$16.13M
Total Cash (Recent Filing)$11.20M
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Mar 27, 2025EPS Estimate
-$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding8,700,389
10 Day Avg. Volume214,605
30 Day Avg. Volume51,577
Standard Deviation0.23
R-Squared0.08
Alpha-0.00994
Financial Highlights & Ratios
Price to Book (P/B)-15.94
Price to Sales (P/S)13.78
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.03
Enterprise Value/Gross Profit5.74
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$12.00Price Target Upside342.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Daré Bioscience News
PremiumCompany Announcements
Daré Bioscience Advances Sildenafil Cream to Phase 3 Study
PremiumCompany Announcements
Daré Bioscience: Advancing Women’s Health Innovations
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe FDA's agreement on just a 12-week treatment period for the Phase 3 trial of sildenafil cream is significant, as FDA guidance typically requires at least 24 weeks of blinded treatment.
Funding And Financial SupportDaré secured a $10.7M grant from the Gates Foundation to support the Ovaprene program, with plans to expand clinical sites, potentially accelerating enrollment.
Strategic PartnershipsBayer may exercise its commercial option for Ovaprene after Phase 3 readout, potentially bringing in an additional $20M, showcasing strong strategic interest from larger players in women's health.
Bears Say
Capital NeedsDaré faces financial risks as it requires capital greater than its current cash balance and may need to raise additional funds, which could be dilutive.
Financial Performance3Q24 revenue came in below the estimate of $3.1M and the Street consensus of $1M.
Regulatory And Commercial RisksThere are regulatory risks involved for Daré as approval is needed for the products in development, and commercial risks due to competition and Covid-19.
---
Ownership Overview
12.23%
Insiders
4.32% Mutual Funds
1.29% Other Institutional Investors
78.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $2.67 and its highest was $10.72 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Currently, no data Available
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Nov 14, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.685 by $0.135.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -$0.53.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 8,700,389 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.685. Following the earnings report the stock price went down -9.831%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
---
Daré Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (342.80% Upside)
$12.00 (342.80% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.92%
Trailing 12-Months
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
---
DARE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including substantial nondilutive funding, progress in product pipeline and clinical trials, and steady market progress for XACIATO. However, challenges remain with decreased R&D spending, operational hurdles for Sildefanil Cream, and overall financial losses.Read More>---
DARE Stock 12 Month Forecast
Average Price Target
$12.00
▲(342.80% Upside)
Technical Analysis
Best Analysts Covering DARE
1 Year
1 Year Success Rate
0/21 ratings generated profit
1 Year Average Return
-44.71%
reiterated a buy rating 5 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -44.71% per trade.
---